Search results for: Richard K. Valicenti

Items from 1 to 20 out of 58 results

article

PSMA guided approach for bIoCHEmical relapse after prostatectomy‐ (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga‐PSMA PET/CT within a prospective study

Giulio Francolini, Marco Banini, Vanessa Di Cataldo, Beatrice Detti, more

Background Ultrasensitive imaging has been demonstrated to influence biochemical relapse treatment. PSICHE is a multicentric prospective study, aimed at exploring detection rate with 68Ga‐PSMA‐11 positron emission tomography/computed tomography (PET/CT) and outcomes with a predefined treatment algorithm tailored to the imaging. Methods Patients affected by biochemical recurrence after surgery (prostate...

article

Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126

Andrew M. McDonald, Lyudmila DeMora, Eddy S. Yang, John M. Hoyle, more

Cancer > 129 > 5 > 685 - 696

Purpose To validate the association between body composition and mortality in men treated with radiation for localized prostate cancer (PCa). Secondarily, to integrate body composition as a factor to classify patients by risk of all‐cause mortality. Materials and Methods Participants of NRG/Radiation Therapy Oncology Group (RTOG) 9406 and NRG/RTOG 0126 with archived computed tomography were included...

article

Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site

Heather M. McGee, Megan E. Daly, Sohelia Azghadi, Susan L. Stewart, more

International Journal of Radiation Oncology*Biology*Physics > 2018 > 101 > 5 > 1259-1270

Despite the strong interest in combining stereotactic ablative radiation therapy (SAR) with immunotherapy, limited data characterizing the systemic immune response after SAR are available. We hypothesized that the systemic immune response to SAR would differ by irradiated site owing to inherent differences in the microenvironment of various organs.Patients receiving SAR to any organ underwent prospective...

article

First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy

Richard K. Valicenti, Stephanie L. Pugh, Edouard J. Trabulsi, Oliver Sartor, more

International Journal of Radiation Oncology*Biology*Physics > 2018 > 100 > 3 > 695-701

To investigate the utility of ¹⁵³Sm lexidronam (Quadramet) in the setting of men with prostate cancer status post radical prostatectomy who develop biochemical failure with no clinical evidence of osseous metastases.Trial NRG Oncology RTOG 0622 is a single-arm phase 2 trial that enrolled men with pT2-T4, N0-1, M0 prostate cancer status post radical prostatectomy, who meet at least 1 of these biochemical...

article

Sustainable Gynecological Brachytherapy in an Increasingly Cost-Aware Healthcare System: Conversion of Labor-Intense Interstitial Brachytherapy to Hybrid Intracavitary Brachytherapy for Locally Advanced Cervical Cancer

Brandon A. Dyer, Stanley Benedict, Yi Rong, Sonja Dieterich, more

Brachytherapy > 2017 > 16 > 3(S) > S58-S59

article

Postoperative Radiation After Radical Prostatectomy

Eric C. Ko, Anthony L. Michaud, Richard K. Valicenti

Seminars in Radiation Oncology > 2017 > 27 > 1 > 50-66

A total of 3 randomized clinical trials have demonstrated a significant clinical benefit with adjuvant radiation in patients with high-risk prostate cancer after radical prostatectomy, with each showing improved biochemical control outcomes, and one trial (SWOG 8794) also demonstrating increased overall survival. How broadly these results have informed clinical practice has evolved over time, given...

chapter

Management of PSA Recurrence After Definitive Therapy for Prostate Cancer

Ilia S. Zeltser, Richard K. Valicenti, Leonard G. Gomella

Current Clinical Urology > Management of Prostate Cancer > Advanced Disease > 525-551

The field of prostate cancer has witnessed dramatic improvements in the management of localized prostate cancer over the last 20 yr. It is thought that stage migration, probably because of screening efforts, combined with improvements in treatment modalities, is largely responsible for these outcomes. The initiation of prostate-specific antigen (PSA) screening has led not only to earlier detection...

article

Image-Guided Brachtherapy for Locally Advanced Cervical Cancer: Can Deformable Image Registration Replace MRI Simulation?

Lauren Tait, Sonja Dieterich, Jihoon Lim, Jon-Paul Hunt, more

Brachytherapy > 2014 > 13 > Supplement 1 > S31

article

Intraoperative Prostate Volume Change During Permanent Low-Dose-Rate I-125 Prostate Brachytherapy: Implications for Final Implant Dosimetry

David E. Greene, Sonja Dieterich, Richard K. Valicenti

Brachytherapy > 2014 > 13 > Supplement 1 > S118

article

The impact of concurrent granulocyte–macrophage colony-stimulating factor on quality of life in head and neck cancer patients: results of the randomized, placebo-controlled Radiation Therapy Oncology Group 9901 trial

Karen E. Hoffman, Stephanie L. Pugh, Jennifer L. James, Charles Scarantino, more

Quality of Life Research > 2014 > 23 > 6 > 1841-1858

Purpose The Radiation Therapy Oncology Group (RTOG) conducted a randomized, placebo-controlled trial evaluating the efficacy of GM-CSF in reducing mucosal injury and symptom burden from curative radiotherapy for head and neck (H&N) cancer. Methods Eligible patients with H&N cancer receiving radiation encompassing ≥50 % of the oral cavity or oropharynx received subcutaneous GM-CSF or placebo...

article

Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Guideline

Ian M. Thompson, Richard K. Valicenti, Peter Albertsen, Brian J. Davis, more

The Journal of Urology > 2013 > 190 > 2 > 441-449

The purpose of this guideline is to provide a clinical framework for the use of radiotherapy after radical prostatectomy as adjuvant or salvage therapy. A systematic literature review using the PubMed®, Embase, and Cochrane databases was conducted to identify peer-reviewed publications relevant to the use of radiotherapy after prostatectomy. The review yielded 294 articles; these publications were...

article

Adjuvant and Salvage Radiation Therapy After Prostatectomy: American Society for Radiation Oncology/American Urological Association Guidelines

Richard K. Valicenti, Ian Thompson, Peter Albertsen, Brian J. Davis, more

International Journal of Radiation Oncology, Biology, Physics > 2013 > 86 > 5 > 822-828

The purpose of this guideline was to provide a clinical framework for the use of radiation therapy after radical prostatectomy as adjuvant or salvage therapy.A systematic literature review using PubMed, Embase, and Cochrane database was conducted to identify peer-reviewed publications relevant to the use of radiation therapy after prostatectomy. The review yielded 294 articles; these publications...

article

Failure Mode and Effect Analysis for Delivery of Lung Stereotactic Body Radiation Therapy

Julian R. Perks, Sinisa Stanic, Robin L. Stern, Barbara Henk, more

International Journal of Radiation Oncology, Biology, Physics > 2012 > 83 > 4 > 1324-1329

To improve the quality and safety of our practice of stereotactic body radiation therapy (SBRT), we analyzed the process following the failure mode and effects analysis (FMEA) method.The FMEA was performed by a multidisciplinary team. For each step in the SBRT delivery process, a potential failure occurrence was derived and three factors were assessed: the probability of each occurrence, the severity...

article

Clinical Outcome of Patients Treated With 3D Conformal Radiation Therapy (3D-CRT) for Prostate Cancer on RTOG 9406

Jeff Michalski, Kathryn Winter, Mack Roach, Arnold Markoe, more

International Journal of Radiation Oncology, Biology, Physics > 2012 > 83 > 3 > e363-e370

Report of clinical cancer control outcomes on Radiation Therapy Oncology Group (RTOG) 9406, a three-dimensional conformal radiation therapy (3D-CRT) dose escalation trial for localized adenocarcinoma of the prostate.RTOG 9406 is a Phase I/II multi-institutional dose escalation study of 3D-CRT for men with localized prostate cancer. Patients were registered on five sequential dose levels: 68.4 Gy,...

article

Relationship Between Pelvic Organ-at-Risk Dose and Clinical Target Volume in Postprostatectomy Patients Receiving Intensity-Modulated Radiotherapy

Sinisa Stanic, Mathew Mathai, Jing Cui, James A. Purdy, more

International Journal of Radiation Oncology, Biology, Physics > 2012 > 82 > 5 > 1897-1902

To investigate dose–volume consequences of inclusion of the seminal vesicle (SV) bed in the clinical target volume (CTV) for the rectum and bladder using biological response indices in postprostatectomy patients receiving intensity-modulated radiotherapy (IMRT).We studied 10 consecutive patients who underwent prostatectomy for prostate cancer and subsequently received adjuvant or salvage RT to the...

article

Does Hormone Therapy Reduce Disease Recurrence in Prostate Cancer Patients Receiving Dose-Escalated Radiation Therapy? An Analysis of Radiation Therapy Oncology Group 94-06

Richard K. Valicenti, Kwounghwa Bae, Jeff Michalski, Howard Sandler, more

International Journal of Radiation Oncology, Biology, Physics > 2011 > 79 > 5 > 1323-1329

The purpose of this study was to evaluate the effect on freedom from biochemical failure (bNED) or disease-free survival (DFS) by adding hormone therapy (HT) to dose-escalated radiation therapy (HDRT).We used 883 analyzable prostate cancer patients who enrolled on Radiation Therapy Oncology Group (RTOG) 94-06, a Phase I/II dose escalation trial, and whose mean planning target volume dose exceeded...

article

A Phase I Trial of Samarium-153-Lexidronam Complex for Treatment of Clinically Nonmetastatic High-Risk Prostate Cancer: First Report of a Completed Study

Richard K. Valicenti, Edouard Trabulsi, Charles Intenzo, Jorosali Lavarino, more

International Journal of Radiation Oncology, Biology, Physics > 2011 > 79 > 3 > 732-737

We completed a Phase I trial to determine the maximum tolerated dose of samarium-153 EDTMP ( ¹⁵³ Sm) with hormonal therapy (HT) and radiation therapy (RT) in high-risk clinically nonmetastatic prostate cancer.High-risk M0 prostate cancer patients (prostate-specific antigen >20 ng/mL, Gleason score >7, or >T3) were eligible for this prospective trial of dose-escalated radioactive ...

article

Reply by the Authors

Robert A. Linden, Perry R. Weiner, Leonard G. Gomella, Edouard J. Trabulsi, more

Urology > 2010 > 76 > 3 > 768-769

article

Development of RTOG Consensus Guidelines for the Definition of the Clinical Target Volume for Postoperative Conformal Radiation Therapy for Prostate Cancer

Jeff M. Michalski, Colleen Lawton, Issam El Naqa, Mark Ritter, more

International Journal of Radiation Oncology, Biology, Physics > 2010 > 76 > 2 > 361-368

To define a prostate fossa clinical target volume (PF-CTV) for Radiation Therapy Oncology Group (RTOG) trials using postoperative radiotherapy for prostate cancer.An RTOG-sponsored meeting was held to define an appropriate PF-CTV after radical prostatectomy. Data were presented describing radiographic failure patterns after surgery. Target volumes used in previous trials were reviewed. Using contours...

article

Long-Term Toxicity Following 3D Conformal Radiation Therapy for Prostate Cancer From the RTOG 9406 Phase I/II Dose Escalation Study

Jeff M. Michalski, Kyounghwa Bae, Mack Roach, Arnold M. Markoe, more

International Journal of Radiation Oncology, Biology, Physics > 2010 > 76 > 1 > 14-22

To update the incidence of late toxicity of RTOG 9406, a three-dimensional conformal radiation therapy (3DCRT) dose escalation trial for prostate cancer.A total of 1,084 men were registered to this Phase I/II trial of 3DCRT (eligible patients, 1,055). The dose for level I was 68.4 Gy; 73.8 Gy for level II; 79.2 Gy for level III; 74 Gy for level IV; and 78 Gy for level V. Patients in levels I to III...

Publication date

Last 3 years (2)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

INFONA - science communication portal

Search results for: Richard K. Valicenti

PSMA guided approach for bIoCHEmical relapse after prostatectomy‐ (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga‐PSMA PET/CT within a prospective study

Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126

Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site

First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy

Sustainable Gynecological Brachytherapy in an Increasingly Cost-Aware Healthcare System: Conversion of Labor-Intense Interstitial Brachytherapy to Hybrid Intracavitary Brachytherapy for Locally Advanced Cervical Cancer

Postoperative Radiation After Radical Prostatectomy

Management of PSA Recurrence After Definitive Therapy for Prostate Cancer

Image-Guided Brachtherapy for Locally Advanced Cervical Cancer: Can Deformable Image Registration Replace MRI Simulation?

Intraoperative Prostate Volume Change During Permanent Low-Dose-Rate I-125 Prostate Brachytherapy: Implications for Final Implant Dosimetry

The impact of concurrent granulocyte–macrophage colony-stimulating factor on quality of life in head and neck cancer patients: results of the randomized, placebo-controlled Radiation Therapy Oncology Group 9901 trial

Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Guideline

Adjuvant and Salvage Radiation Therapy After Prostatectomy: American Society for Radiation Oncology/American Urological Association Guidelines

Failure Mode and Effect Analysis for Delivery of Lung Stereotactic Body Radiation Therapy

Clinical Outcome of Patients Treated With 3D Conformal Radiation Therapy (3D-CRT) for Prostate Cancer on RTOG 9406

Relationship Between Pelvic Organ-at-Risk Dose and Clinical Target Volume in Postprostatectomy Patients Receiving Intensity-Modulated Radiotherapy

Does Hormone Therapy Reduce Disease Recurrence in Prostate Cancer Patients Receiving Dose-Escalated Radiation Therapy? An Analysis of Radiation Therapy Oncology Group 94-06

A Phase I Trial of Samarium-153-Lexidronam Complex for Treatment of Clinically Nonmetastatic High-Risk Prostate Cancer: First Report of a Completed Study

Reply by the Authors

Development of RTOG Consensus Guidelines for the Definition of the Clinical Target Volume for Postoperative Conformal Radiation Therapy for Prostate Cancer

Long-Term Toxicity Following 3D Conformal Radiation Therapy for Prostate Cancer From the RTOG 9406 Phase I/II Dose Escalation Study

Filter options

Publication date

Content availability

Publication type

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: Richard K. Valicenti

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Content availability

Publication type

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options